Tezruly is a drug owned by Novitium Pharma Llc. It is protected by 2 US drug patents filed from 2024 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 01, 2041. Details of Tezruly's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11224572 | Stable oral liquid composition of terazosin |
Feb, 2041
(14 years from now) | Active |
| US12427108 | Stable Oral Liquid Composition Of Terazosin |
Feb, 2041
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tezruly's patents.
Latest Legal Activities on Tezruly's Patents
Given below is the list of recent legal activities going on the following patents of Tezruly.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Application Is Considered Ready for Issue | 11 Sep, 2025 | US12427108 |
| Dispatch to FDC | 11 Sep, 2025 | US12427108 |
| Issue Fee Payment Received | 09 Sep, 2025 | US12427108 |
| Issue Fee Payment Verified | 09 Sep, 2025 | US12427108 |
| Email Notification | 18 Jul, 2025 | US12427108 |
| Mail Notice of Allowance | 18 Jul, 2025 | US12427108 |
| Notice of Allowance Data Verification Completed | 17 Jul, 2025 | US12427108 |
| Date Forwarded to Examiner | 18 Jun, 2025 | US12427108 |
| Response after Non-Final Action | 13 Jun, 2025 | US12427108 |
| Electronic Review | 03 Jun, 2025 | US12427108 |
US patents provide insights into the exclusivity only within the United States, but
Tezruly is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tezruly's family patents as well as insights into
ongoing legal events
on those patents.
Tezruly's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tezruly's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 01, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tezruly Generic API suppliers:
Terazosin Hydrochloride is the generic name for the brand Tezruly. 12 different companies have already filed for the generic of Tezruly, with Pharmobedient having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tezruly's generic
Alternative Brands for Tezruly
There are several other brand drugs using the same active ingredient (Terazosin Hydrochloride) as Tezruly. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbott |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Terazosin Hydrochloride, Tezruly's active ingredient. Check the complete list of approved generic manufacturers for Tezruly
About Tezruly
Tezruly is a drug owned by Novitium Pharma Llc. Tezruly uses Terazosin Hydrochloride as an active ingredient. Tezruly was launched by Novitium in 2024.
Approval Date:
Tezruly was approved by FDA for market use on 29 July, 2024.
Active Ingredient:
Tezruly uses Terazosin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Terazosin Hydrochloride ingredient
Dosage:
Tezruly is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1MG BASE/ML | SOLUTION | Discontinued | ORAL |